What is Mercy Bioanalytics?
Mercy Bioanalytics is a pioneering biotechnology company dedicated to the early detection of cancer, with the ultimate goal of reducing suffering and saving lives. The company leverages a novel approach utilizing nanoparticles found abundantly in blood, known as extracellular vesicles (EVs). These EVs carry crucial information from their parent cells, enabling Mercy Bioanalytics to develop a promising method for identifying early-stage cancers when they are most treatable. The company's initial strategic focus is on detecting difficult-to-diagnose cancers such as ovarian and lung cancer, which are frequently diagnosed at later, less treatable stages. This focus on early detection positions Mercy Bioanalytics at the forefront of a critical unmet need in oncology diagnostics.
How much funding has Mercy Bioanalytics raised?
Mercy Bioanalytics has raised a total of $100M across 2 funding rounds:
Series A
$41M
Series B
$59M
Series A (2023): $41M with participation from Hatteras Venture Partners, Sozo Ventures, Novalis LifeSciences, and iSelect Fund Management
Series B (2025): $59M led by Bruker Scientific, Avestria Ventures Management, BrightEdge - American Cancer Society, Novalis Trust, iSelect Fund Management, Xontogeny, Portfolia, Hologic, Sozo Ventures, and Labcorp
Key Investors in Mercy Bioanalytics
Bruker Scientific
Bruker Scientific LLC is involved in the office products retail and distribution industry, suggesting a potential interest in the operational and supply chain aspects of scaling a biotechnology company.
Avestria Ventures Management
Avestria Ventures Management is a venture capital firm specializing in early-stage women's health and life science companies, indicating a focus on innovative healthcare solutions and potentially supporting companies with strong female leadership or addressing health disparities.
BrightEdge - American Cancer Society
BrightEdge, the investment arm of the American Cancer Society, focuses on driving scientific, social, and sustainable impact across cancer care, aligning perfectly with Mercy Bioanalytics' mission to combat cancer through early detection.
What's next for Mercy Bioanalytics?
With the recent major strategic investment, Mercy Bioanalytics is poised for accelerated growth and the expansion of its diagnostic capabilities. This substantial capital injection, following a history of major enterprise-level funding, will likely fuel further research and development, clinical validation, and the scaling of manufacturing processes. The company's progression through Series A and now Series B funding rounds indicates a maturing lifecycle stage, moving from development towards commercialization and market penetration. Investors such as Bruker Scientific, Avestria Ventures Management, and BrightEdge - American Cancer Society, with their diverse expertise in scientific instrumentation, life sciences, and cancer-focused initiatives, suggest a strategic alignment to support Mercy Bioanalytics' mission. The company is expected to enhance its efforts in bringing its early cancer detection technology to a wider patient population, potentially transforming cancer care paradigms.
See full Mercy Bioanalytics company page
